Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Focal therapy targets prostate lesions visible on MRI using heat, cold, laser, or HIFU, aiming to avoid the incontinence and erectile dysfunction common with full-gland surgery or radiation, and was a major topic at the recent annual urology meeting.
- A U.K. study found that 10 years after focal therapy, only 0.1% of patients had died of prostate cancer — comparable to standard treatments — with higher satisfaction and fewer side effects, bolstering providers who already offer it.
- The American Urological Association still labels focal therapy experimental, limiting it to intermediate-risk patients in studies or registries, and a recent paper found half of focal therapy recipients were either higher- or lower-risk than guidelines recommend.
- Technology mix has shifted sharply: cryotherapy dropped from ~80% of focal procedures in 2010 to ~20% by 2023, while laser ablation reached ~45% and HIFU grew to ~35%.
- U.S. uptake remains minimal: only 1.3% of prostate cancer patients receive it, and many pay out of pocket — Denver patient Chris Brosseau spent about $17,000 — because commercial insurers often won't cover it, though Medicare does.
- Skeptics led by UCSD's Tyler Seibert argue focal therapy has never been tested in a head-to-head randomized trial against surgery or radiation, calling the absence of that evidence the field's core unresolved problem.
Why it matters: Roughly 1.3% of U.S. prostate cancer patients get focal therapy despite Medicare coverage and 10-year survival data matching standard care, because commercial insurers still won't pay and the AUA withholds a full endorsement pending randomized trials — meaning access hinges on which side of the divide a patient's provider sits on and whether they can afford $17,000 out of pocket.
Ask SkimNews
